Mr. Thomas Smeenk reports

DR. ERNST VON SCHWARZ, PRINCIPAL INVESTIGATOR OF HEMOSTEMIX VESCELL LONGEVITY CLINICAL TRIAL

Hemostemix Inc. has appointed Prof. Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI, as principal investigator of Hemostemix's VesCell (ACP-01) longevity clinical trial.

The study is designed to investigate whether Hemostemix's VesCell can improve measurable dimensions of longevity including cardiovascular health associated with health span (healthy active aging), improvements in muscle function as measured by the six minute walk test, cognitive function and immune system improvement as measured by decreased inflammation.

About Prof. Dr. Ernst von Schwarz

Dr. von Schwarz brings more than three decades of cardiovascular, academic and regenerative-medicine experience to the study. Triple board certified as a transplant surgeon, cardiologist and physician-scientist at Cedars-Sinai Medical Center and UCLA, Dr. von Schwarz has published more than 150 scientific papers, including as co-author of Hemostemix's retrospective study evaluating transcatheter implantation of VesCell in patients with ischemic and non-ischemic cardiomyopathy. He joined Hemostemix's scientific advisory board in 2022; and, he joined phase II investigator Dr. York Hsiang in Hemostemix's educational webinar, When Standard Heart Treatment Isn't Enough, May, 2026.

Most recently, Dr. von Schwarz is the featured expert in HeartCode, a powerful and emotionally charged documentary that details how most heart-related deaths are preventable and how longevity is achievable. "There is an important connection between cardiovascular health and longevity: our organs cannot remain healthy without adequate circulation," said Dr. von Schwarz. "The VesCell data to date supports a properly designed longevity study, to measure whether cardiovascular function, physical capacity, quality of life and other objective markers of health span can be preserved and improved; and, I look forward to answer these questions rigorously," he said.

From restoring circulation to extending health span: longevity

The longevity trial is designed to generate clinical evidence that support participation in health-span competitions, some which offer up to $101-million (U.S.) in prize funding to accelerate innovations that improve healthy human aging. One such competition measures longevity as increases in muscle capacity as defined by the six-minute walk test, improved cognition and immune system function, which Hemostemix's clinical results mirror.

For example, in the study co-authored by Dr. von Schwarz, subjects with a left ventricle ejection fraction below 20 per cent improved from a mean LVEF of 14.6 per cent before treatment to 28.4 per cent at final follow-up, representing a 94.5-per-cent relative improvement (p less than 0.003), which is consistent with improvement in subjects' six-minute walk test.

Improved six-minute walk test and improved heart function: In the phase I Angina trial, mean six-minute walk distance increased 81.3 metres post treatment at three months, p less than 0.001 and remained as an increase of 79.6 metres at six months from baseline, p less than 0.001 (Tresukosol et al., 2006). In the same study, the proportion of heart that was suffering from inadequate blood circulation improved 45.3 per cent: myocardial perfusion defects decreased 37.9 per cent at three months, p less than 0.004, and decreased by 45.3 per cent at six months from baseline, p less than 0.005 (Tresukosol et al., 2006).

Reversal of heart failure as measured by NYHA classification: The New York Heart Association (NYHA) classification grades heart failure from Class I, where normal activity causes no symptoms, to Class IV (end stage), where shortness of breathe and chest symptoms occur even at rest. In Hemostemix's 41-patient phase I, NYHA classification decreased from Class IV/III to Class III/II at 180 days, p less than 0.05, reflecting substantially better daily function and fewer heart-failure symptoms (Arom et al., 2008).

In Hemostemix's phase I ischemic cardiomyopathy study, 30 patients with paired SF-36 assessments at three and six months showed increases across all eight quality-of-life domains, with statistically significant improvements:

• 58-per-cent improvement in physical functioning from 37.83 to 60.09 -- an increase of 22.26 points, p less than 0.001;
• 92-per-cent improvement in role limitations due to physical health from 31.89 to 61.21 -- up 29.32, p less than 0.001;
• 56-per-cent improvement in general health from 34.79 to 54.57 -- up 19.78 points, p less than 0.001;
• 48.6-per-cent improvement in vitality from 39.58 to 58.82 -- up 19.24 points, p equals 0.001;
• 24-per-cent improvement in social functioning from 60.83 to 75.42 -- up 14.59 points, p equals 0.014;
• 30.8-per-cent improvement in the physical component summary, from 30.75 to 40.21, up 9.46 points, p less than 0.001.

VesCell vascular dementia case study: Before treatment, Ms. L. had experienced a loss of executive function, short- and long-term memory, judgment, and the ability to perform the activities of daily living. Seven years post treatment, in a telephone call with four physicians and Thomas Smeenk, Ms. L reported that within six months of her VesCell treatment, she regained her ability to live independently. During the 12 minute call, Ms. L clearly recalled her "wonderful" treatment experience, her career, child bearing years and family, and her active social calendar, with the ease of a cognitively healthy individual.

SF 36 survey and P values explained: The SF-36 is a validated questionnaire that measures changes in quality of life based on physical health, pain, energy, emotional well-being and ability to perform everyday activities. A result of p less than 0.05 means there is less than a 5-per-cent probability that the observed difference arose from random variation alone, the conventional threshold for statistical significance. In Hemostemix's clinical trials, findings less than p less than 0.05 provide increasingly strong evidence that the improvements were not due to chance.

"Dr. von Schwarz is uniquely qualified to lead this study because his career sits precisely at the intersection of cardiovascular medicine, regenerative medicine and longevity," said Thomas Smeenk, chief executive officer. "Combined with his work on HeartCode, Dr. von Schwarz is recognized as an expert who details how to extend healthy, fully functional life well past age 100! That is a very significant global business for Hemostemix," Mr. Smeenk said.

About Hemostemix Inc.

Hemostemix is an autologous stem-cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell an investigational autologous stem-cell therapy developed to support circulation in areas affected by diseases of ischemia. VesCell is derived from a patient's own blood and evaluated through structured clinical research. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer-reviewed publications. ACP-01 is safe, and appears clinically relevant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase II clinical trial for chronic limb-threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 50 per cent in the CLTI diabetes-based patient population, University of British Columbia and University of Toronto reported to the 41st meeting of vascular surgeons: 0-per-cent mortality, cessation of pain, wound healing in 83 per cent of patients followed for up to 4.5 years, as a mid-point result.

We seek Safe Harbor.